211 related articles for article (PubMed ID: 24285256)
21. The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients.
Provenzani A; Notarbartolo M; Labbozzetta M; Poma P; Biondi F; Sanguedolce R; Vizzini G; Palazzo U; Polidori P; Triolo F; Gridelli B; D'Alessandro N
Ann Transplant; 2009; 14(1):23-31. PubMed ID: 19289993
[TBL] [Abstract][Full Text] [Related]
22. Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China.
Meng XG; Guo CX; Feng GQ; Zhao YC; Zhou BT; Han JL; Chen X; Shi Y; Shi HY; Yin JY; Peng XD; Pei Q; Zhang W; Wang G; He M; Liu M; Yang JK; Zhou HH
Acta Pharmacol Sin; 2012 Dec; 33(12):1563-70. PubMed ID: 23085740
[TBL] [Abstract][Full Text] [Related]
23. Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant.
Rodríguez-Jiménez C; García-Saiz M; Pérez-Tamajón L; Salido E; Torres A
Drug Metab Pers Ther; 2017 Mar; 32(1):49-58. PubMed ID: 28245187
[TBL] [Abstract][Full Text] [Related]
24. Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype.
Vanhove T; Annaert P; Lambrechts D; Kuypers DRJ
Pharmacogenomics J; 2017 Dec; 17(6):556-562. PubMed ID: 27378609
[TBL] [Abstract][Full Text] [Related]
25. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
[TBL] [Abstract][Full Text] [Related]
26. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.
Żochowska D; Wyzgał J; Pączek L
Ann Transplant; 2012; 17(3):36-44. PubMed ID: 23018254
[TBL] [Abstract][Full Text] [Related]
27. Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients.
Qiu F; He XJ; Sun YX; Li-Ling J; Zhao LM
Pharmacol Rep; 2011; 63(3):815-25. PubMed ID: 21857093
[TBL] [Abstract][Full Text] [Related]
28. Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients.
Sam WJ; Chamberlain CE; Lee SJ; Goldstein JA; Hale DA; Mannon RB; Kirk AD; Hon YY
Transplantation; 2012 Nov; 94(9):971-7. PubMed ID: 23073467
[TBL] [Abstract][Full Text] [Related]
29. CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients.
Li Y; Yan L; Shi Y; Bai Y; Tang J; Wang L
Springerplus; 2015; 4():637. PubMed ID: 26543771
[TBL] [Abstract][Full Text] [Related]
30. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.
Glowacki F; Lionet A; Buob D; Labalette M; Allorge D; Provôt F; Hazzan M; Noël C; Broly F; Cauffiez C
Nephrol Dial Transplant; 2011 Sep; 26(9):3046-50. PubMed ID: 21677300
[TBL] [Abstract][Full Text] [Related]
31. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
[TBL] [Abstract][Full Text] [Related]
32. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
[TBL] [Abstract][Full Text] [Related]
33. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study.
Haufroid V; Wallemacq P; VanKerckhove V; Elens L; De Meyer M; Eddour DC; Malaise J; Lison D; Mourad M
Am J Transplant; 2006 Nov; 6(11):2706-13. PubMed ID: 17049058
[TBL] [Abstract][Full Text] [Related]
34. Polymorphisms in CYP3A5*3 and MDR1, and haplotype modulate response to plasma levels of tacrolimus in Chinese renal transplant patients.
Wu P; Ni X; Wang M; Xu X; Luo G; Jiang Y
Ann Transplant; 2011; 16(1):54-60. PubMed ID: 21436775
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.
Santoro A; Felipe CR; Tedesco-Silva H; Medina-Pestana JO; Struchiner CJ; Ojopi EB; Suarez-Kurtz G
Pharmacogenomics; 2011 Sep; 12(9):1293-303. PubMed ID: 21806386
[TBL] [Abstract][Full Text] [Related]
36. Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.
Chen P; Li J; Li J; Deng R; Fu Q; Chen J; Huang M; Chen X; Wang C
J Clin Pharm Ther; 2017 Feb; 42(1):93-97. PubMed ID: 27885697
[TBL] [Abstract][Full Text] [Related]
37. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients.
Crettol S; Venetz JP; Fontana M; Aubert JD; Pascual M; Eap CB
Ther Drug Monit; 2008 Dec; 30(6):689-99. PubMed ID: 18978522
[TBL] [Abstract][Full Text] [Related]
38. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids.
Mourad M; Mourad G; Wallemacq P; Garrigue V; Van Bellingen C; Van Kerckhove V; De Meyer M; Malaise J; Eddour DC; Lison D; Squifflet JP; Haufroid V
Transplantation; 2005 Oct; 80(7):977-84. PubMed ID: 16249748
[TBL] [Abstract][Full Text] [Related]
39. Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients.
Sallustio BC; Noll BD; Hu R; Barratt DT; Tuke J; Coller JK; Russ GR; Somogyi AA
Br J Clin Pharmacol; 2021 Oct; 87(10):3901-3909. PubMed ID: 33646566
[TBL] [Abstract][Full Text] [Related]
40. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
Rong G; Jing L; Deng-Qing L; Hong-Shan Z; Shai-Hong Z; Xin-Min N
Transplant Proc; 2010 Nov; 42(9):3455-8. PubMed ID: 21094796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
